Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Galderma Group AG
Industry Sector: HealthTechnology
CEO: Flemming Ørnskov, MD, MBA
Number Of Employees: N/A
Enterprise Value: N/A
PE Ratio: 49.38
Exchange/Ticker 1: SIX:GALD
Exchange/Ticker 2: N/A
Latest Market Cap: $24,225,524,547
BioCentury | Jan 10, 2025
Data Byte
FDA’s new and supplemental approvals in December
Agency approves at least nine new therapies; adds new indications or patient populations to a dozen marketed drugs
BioCentury | Dec 14, 2024
Data Byte
BridgeBio, Geron follow U.S. approvals with nods from EMA’s CHMP
November meeting highlights also include a pair of firsts for rare genetic diseases, and label expansions for eight approved drugs
BioCentury | Sep 5, 2024
Data Byte
FDA’s new drug approvals in August include a Dupixent competitor, a targeted glioma therapy, and more
Agency approved seven new therapies in August, plus four new product formulations or dosages
BioCentury | Sep 4, 2024
Finance
Light from the IPO window
Six recent filings may mean appetite for new listings is on the rise
BioCentury | Aug 13, 2024
Data Byte
Summer lull as FDA approves only 2 NMEs in July
Total for the year stands at 26, lagging last year
BioCentury | Mar 22, 2024
Finance
Public equity report: Galderma rises after $2B IPO; Contineum, Boundless prep U.S. listings
Plus Madrigal’s follow-on is among the year’s largest, and PureTech returns cash to shareholders following Karuna takeout
Items per page:
1 - 6 of 6